<DOC>
	<DOCNO>NCT00004128</DOCNO>
	<brief_summary>RATIONALE : Giving combination chemotherapy peripheral blood stem cell transplant stop growth cancer cell stop divide kill . After treatment , stem cell collect patient 's blood bone marrow store . More chemotherapy radiation therapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy radiation therapy . Interleukin-2 may stimulate patient 's white blood cell kill cancer cell . PURPOSE : This randomized phase III trial study two different regimen combination chemotherapy , interleukin-2 , peripheral stem cell transplant compare see well work treat patient acute myeloid leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy , Interleukin-2 , Peripheral Stem Cell Transplant Treating Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival rate patient acute myeloid leukemia treat high-dose versus standard-dose cytarabine induction . - Compare disease-free survival rate patient treat without interleukin-2 follow consolidation autologous peripheral blood stem cell bone marrow transplantation . - Compare feasibility regimens patient . OUTLINE : This randomize , multicenter study . Patients first randomization stratify accord center , WBC ( great 25,000/mm^3 vs 25,000-99,000/mm^3 v least 100,000/mm^3 ) , age ( 15 45 v 46 60 ) , performance status ( 0-1 v 2 v 3 ) . Patients second randomization stratify accord center , first treatment arm ( I vs II ) , number induction course reach complete remission ( CR ) , cytogenic/molecular genetic group diagnosis ( low vs high v intermediate v unknown ) , autologous peripheral blood stem cell ( PBSC ) transplantation plan consolidation ( yes v ) . First randomization - Induction : Patients randomize 1 2 treatment arm : - Arm I : Patients receive standard-dose cytarabine IV 24 hour day 1-10 , etoposide IV 1 hour day 1-5 , daunorubicin IV 5 minute day 1 , 3 , 5 . - Arm II : Patients receive etoposide daunorubicin arm I high-dose cytarabine IV 3 hour every 12 hour day 1 , 3 , 5 , 7 . - Consolidation : When CR reach , patient receive intermediate-dose cytarabine IV 2 hour every 12 hour day 1-6 daunorubicin IV 5 minute prior cytarabine day 4 , 5 , 6 . - Harvest : Patients achieve CR ineligible allogeneic PBSC transplantation receive filgrastim ( G-CSF ) subcutaneously ( SQ ) every 12 hour begin 20 day start consolidation treatment continue autologous PBSC harvest . Autologous bone marrow collect patient insufficient PBSC . Allogeneic PBSC harvest patient HLA identical donor . Allogeneic bone marrow harvest high risk patient ( age 40 ) unrelated bone marrow donor . - Transplant preparative chemotherapy : It recommend patient receive cyclophosphamide 2 consecutive day total body irradiation 3 day OR busulfan day -8 , -7 , -6 , -5 follow cyclophosphamide day -4 -3 . - Transplantation : PBSC bone marrow infuse day 0 . Second randomization - Patients achieve CR full hematologic recovery HLA identical donor randomize 1 2 treatment arm earlier day 22 stem cell infusion . - Arm I : Patients receive interleukin-2 SQ daily 5 day . Treatment repeat every 4 week 1 year absence disease progression unacceptable toxicity . - Arm II : Patients receive treatment . Patients follow 1 , 4 , 13 month , every 4 month 3 year , every 6 month thereafter . PROJECTED ACCRUAL : A total 2,000 patient ( 1,000 per treatment arm ) accrue first randomization total 577 patient ( 288 per treatment arm ) accrue second randomization study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : First randomization : Untreated newly diagnose acute myeloid leukemia ( AML ) At least 30 % blast bone marrow All cytological type AML except acute promyelocytic leukemia ( M3 ) No blast crisis chronic myelogenous leukemia No leukemia supervene myeloproliferative disease No leukemia supervene overt myelodysplastic disorder ( e.g. , refractory anemia excess blast ) 6 month duration Second randomization : Must achieve complete remission full hematologic recovery follow consolidation treatment No HLA identical family donor Not eligible allograft No high risk patient ( age 40 ) unrelated bone marrow donor find within 8 week begin consolidation treatment PATIENT CHARACTERISTICS : Age : 15 60 Performance status : WHO 03 ( first randomization ) WHO 02 ( second randomization ) Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 3 time upper limit normal ( ULN ) Renal : Creatinine great 3 time ULN Cardiovascular : No severe heart failure require diuretic Ejection fraction least 50 % Other : First randomization : No progressive malignant disease except follow : Secondary acute leukemia follow curatively treat Hodgkin 's disease ( even treat anthracyclines ) Other curatively treated malignancy Secondary leukemias follow exposure alkylating agent radiotherapy reason No uncontrolled infection No severe concurrent neurologic psychiatric disease No psychological , familial , sociological , geographical condition could preclude compliance Second randomization : No nonmalignant systemic illness would increase risk participation study No uncontrolled infection No progressive malignant disease PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy AML except hydroxyurea Less 7 day prior hydroxyurea Endocrine therapy : No 7 day prior corticosteroid therapy AML Radiotherapy : No prior radiotherapy AML Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
</DOC>